ARRIVENT BIOPHARMA INC (AVBP) Stock Price, Quote, News and Overview
NASDAQ:AVBP - Nasdaq - US04272N1028 - Common Stock - Currency: USD
AVBP Quote, Performance and Key Statistics
27.07
-0.32 (-1.17%)
The current stock price of AVBP is 27.07 USD. In the past month the price decreased by -0.66%. In the past year, price increased by 40.11%.
AVBP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AVBP
Company Profile
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Newtown Square, Pennsylvania and currently employs 40 full-time employees. The company went IPO on 2024-01-26. The firm is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. The company is also focused on development and commercialization of the ARR-002 program.
Company Info
ARRIVENT BIOPHARMA INC
18 Campus Blvd., Suite 100
Newtown Square PENNSYLVANIA US
Employees: 40
Company Website: https://arrivent.com/
Phone: 12407806356
ARRIVENT BIOPHARMA INC / AVBP FAQ
What is the stock price of ARRIVENT BIOPHARMA INC today?
The current stock price of AVBP is 27.07 USD. The price decreased by -1.17% in the last trading session.
What is the ticker symbol for ARRIVENT BIOPHARMA INC stock?
The exchange symbol of ARRIVENT BIOPHARMA INC is AVBP and it is listed on the Nasdaq exchange.
On which exchange is AVBP stock listed?
AVBP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARRIVENT BIOPHARMA INC stock?
11 analysts have analysed AVBP and the average price target is 39.37 USD. This implies a price increase of 45.45% is expected in the next year compared to the current price of 27.07. Check the ARRIVENT BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARRIVENT BIOPHARMA INC worth?
ARRIVENT BIOPHARMA INC (AVBP) has a market capitalization of 912.26M USD. This makes AVBP a Small Cap stock.
How many employees does ARRIVENT BIOPHARMA INC have?
ARRIVENT BIOPHARMA INC (AVBP) currently has 40 employees.
What are the support and resistance levels for ARRIVENT BIOPHARMA INC (AVBP) stock?
ARRIVENT BIOPHARMA INC (AVBP) has a support level at 26.94 and a resistance level at 27.13. Check the full technical report for a detailed analysis of AVBP support and resistance levels.
Should I buy ARRIVENT BIOPHARMA INC (AVBP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AVBP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AVBP, evaluating the profitability, health, valuation and growth aspects
- ARRIVENT BIOPHARMA INC (AVBP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARRIVENT BIOPHARMA INC (AVBP) Sales and EPS estimates to see what analysts future expectations are.
- ARRIVENT BIOPHARMA INC (AVBP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARRIVENT BIOPHARMA INC (AVBP) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARRIVENT BIOPHARMA INC (AVBP) Stock Chart to make your own analysis
- ARRIVENT BIOPHARMA INC (AVBP) Latest news and press-releases to stay up to date.
Does ARRIVENT BIOPHARMA INC (AVBP) stock pay dividends?
AVBP does not pay a dividend.
What is the Price/Earnings (PE) ratio of ARRIVENT BIOPHARMA INC (AVBP)?
ARRIVENT BIOPHARMA INC (AVBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.62).
What is the Short Interest ratio of ARRIVENT BIOPHARMA INC (AVBP) stock?
The outstanding short interest for ARRIVENT BIOPHARMA INC (AVBP) is 18.69% of its float. Check the ownership tab for more information on the AVBP short interest.
AVBP Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AVBP. When comparing the yearly performance of all stocks, AVBP is one of the better performing stocks in the market, outperforming 85.42% of all stocks.
AVBP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVBP. While AVBP has a great health rating, there are worries on its profitability.
AVBP Financial Highlights
Over the last trailing twelve months AVBP reported a non-GAAP Earnings per Share(EPS) of -2.62. The EPS decreased by -88.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.69% | ||
| ROE | -29.21% | ||
| Debt/Equity | 0 |
AVBP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to AVBP. The Buy consensus is the average rating of analysts ratings from 11 analysts.